1
Memory T cells promote allograft rejection particularly in co-stimulation blockade-based immunosuppressive regimens.
2
This seemed to be useful for early diagnosis of lung allograft rejection.
3
One of the crucial drawbacks in successful renal transplantation is allograft rejection.
4
Chronic cardiac allograft rejection is the major barrier to long term graft survival.
5
Chronic allograft rejection is a major impediment to long-term transplant success.
6
The primary outcome was allograft loss, and the secondary outcome was allograft rejection.
7
Monitoring human cardiac allograft rejection is currently accomplished by endomyocardial biopsy.
8
Duplex ultrasonography has met with variable accuracy in identifying acute renal allograft rejection.
9
Complement deficiency or blockade attenuates T-cell-mediated autoimmunity and delays allograft rejection in mice.
10
Gene expression-based categorization of allograft rejection may prove useful in monitoring lung allograft health.
11
Our data suggest that HTx and allograft rejection alter the circulating exosomal protein content.
12
We hypothesized that gene signatures common to allograft rejection would be present in LB.
13
Newer immunosuppressive agents are further modifying the long term management of liver allograft rejection.
14
Prevention and treatment of allograft rejection remain the major issues in clinical small bowel transplantation.
15
These datas implicate new therapies to prevent OB and allograft rejection in human lung transplantation.
16
Here we suggest a theoretical role for the use of cannabinoids in preventing allograft rejection.
